Clinical trials recruiting in Aschaffenburg, Germany

Phase breakdown

Conditions recruiting in Aschaffenburg, Germany

Recruiting trials in Aschaffenburg, Germany

• A Non-interventional, Prospective Study With Benralizumab
  NCT06422078 · Phase: Not specified · Ages: 18 Years to 120 Years · Sex: All (male and female)
• A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World Setting
  NCT07230691 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Investigate Effects of Ocrelizumab Treatment on Neurofilament Light Chain (NfL) Levels and Participant Satisfaction in Participants With Multiple Sclerosis (MS)
  NCT06780150 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• BRAF Inhibitor Encorafenib And Cetuximab Real Life Investigation of Next Generation CRC Treatment
  NCT04673955 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• Binimetinib Plus Encorafenib Real Life Investigation of Next Generation Melanoma Treatment
  NCT04045691 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• Combination of Abemaciclib and Endocrine Therapy in Hormone Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer With Focus on Digital Side Effect Management
  NCT05362760 · Phase: Phase 4 · Ages: 18 Years and older · Sex: Female
• Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients
  NCT05452213 · Phase: Phase 4 · Ages: 18 Years and older · Sex: Female
• Digital Dementia Registry Bavaria (digiDEM Bayern): a Multicentre, Prospective, Longitudinal Register Study Including People With Mild Cognitive Impairment and Dementia as Well as Their Family Caregivers
  NCT07721701 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female)
• Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.
  NCT06382948 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
  NCT06982521 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Real-World Clinical Experience of Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Olaparib + Abiraterone (PROceed)
  NCT06380738 · Phase: Not specified · Ages: 18 Years and older · Sex: Male
• Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype
  NCT06486883 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)

Common questions

How many clinical trials are recruiting in Aschaffenburg, Germany?

12 recruiting trials have at least one study site in Aschaffenburg, Germany.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.